Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed Mar 1, 2023 · 10-K · 60 days after period end · 0000899923-23-000011
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $177.80M | $160.80M | $154.60M | $195.10M |
| Net Income | -$42.30M | -$7.60M | -$37.90M | -$8.30M |
| EPS Diluted | — | — | -$0.50 | -$0.11 |
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 1, 2023 · 60 d after period end
